

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

March 18, 2015

Analytica Ltd % Tracey Bullivant Consultant Brandwood Biomedical 408, 460 Pacific Highway St Leonards, NSW 2065 AU

Re: K143580

Trade/Device Name: PeriCoach

Regulation Number: 21 CFR 884.1425

Regulation Name: Perineometer

Regulatory Class: Class II

Product Code: HIR

Dated: December 12, 2014 Received: December 18, 2014

Dear Tracey Bullivant,

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-

related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

<u>http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm</u> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Joyce M. Whang -S

For Benjamin Fisher
Director
Division of Reproductive, Gastro-Renal,
and Urological Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure

DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

Indications for Use

Form Approved: OMB No. 0910-0120 Expiration Date: January 31, 2017 See PRA Statement below.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

CONTINUE ON A SEPARATE PAGE IF NEEDED.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

510(k) Summary

Date Prepared: 13 December, 2014

510(k) Owner: Analytica Pty Ltd

320 Adelaide Street, Brisbane, QLD 4000,

Australia

Tel: +61 (0) 732781950

Official Contact: Tracey Bullivant

408, 460 Pacific Highway St Leonards NSW 2065

Australia

Tel: +61(0) 299062984 Fax: +61(0) 285804613

tracey@brandwoodbiomedical.com

Trade Name: PeriCoach®

Common Name: Perineometer

Classification Name: (21CFR 884.1425) Perineometer

Product Code: HIR

Predicate: Neen Healthcare Periform (K002617)

Intended Use: The PeriCoach® is a perineometer designed to treat stress, mild-

moderate urge and mixed urinary incontinence in women, by

strengthening of the pelvic floor muscles through exercise. This device

provides biofeedback via smart phone technology.

Device Description: The PeriCoach® device consists of a rigid probe covered in a silicone

sheath that is temporarily inserted into the vagina. Sensors located under the sheath measure the strength of contraction of the user's pelvic floor muscles. This information is then transmitted wirelessly to a

smartphone application in order to provide real-time feedback to the user. It is a single patient, reusable device to be supplied under

prescription only.

Non-clinical Testing: The patient contacting materials in the PeriCoach have been tested in

accordance with ISO 10993 standards and found to be safe for the

intended purpose. Biocompatibility testing includes Cytotoxicity (ISO 10993-5, 2009), Sensitization (ISO 10993-10, 2010), Vaginal Irritation (ISO 10993-10, 2010), and Systemic Toxicity (ISO 10993-11, 2006).

Electrical safety and electromagnetic compatibility testing have been conducted in accordance with IEC 60601-1:2005, IEC 60601-1-2:2007, and IEC 60601-1-11:2010 to establish the safety of the device. Software verification and validation testing has also been conducted in accordance with IEC 62304:2006.

In addition, various mechanical tests have been conducted to establish substantial equivalence including mechanical drop testing, durability testing, immersion/long term cleaning exposure, and sensor behavior testing. The results of these tests indicate that the device is effective for the intended use.

Summary of Basis for Substantial Equivalence:

| Parameters | Predicate: Periform (K002617) | PeriCoach (New device) |
|------------------------------|---|--|
| Mode of Use | Reusable for single patient | Same |
| Target Population | Adult female urinary incontinence patients | Same |
| Principle of Operation | A probe inserted into the vagina to determine the strength of the pelvic floor muscles. Probe sends signals to external device to indicate muscle contraction strength to encourage and assist user with voluntary kegel exercises. | Same |
| Electrode/sensor orientation | Longitudinal | Same |
| Sensing method | sEMG biofeedback recording (wired electrode). | Output from force sensing resistors (wireless). |
| Parameter monitored | Aggregate surface electromyogram (sEMG). | Analogue to digital output of uncalibrated force exerted against external walls of device by pubococcygeus and puborectalis muscles. |

| Parameters | Predicate: Periform (K002617) | PeriCoach (New device) |
|--|---|--|
| User Feedback | The Periform does not provide feedback directly to the user; a separate external feedback device is required. | The PeriCoach is designed to provide real-time feedback, via an application on the user's Smartphone. The Smartphone application displays the relative magnitudes of pelvic muscle contraction or graphically displays the normalized analogue to digital sensor output depending on which option is selected. |
| Anatomical Sites | Female Pubococcygeus muscle area | Same |
| Where used | Hospitals, Clinics, Doctors' offices or home use under Clinician supervision | Same |
| Energy used and/or delivered | No energy used or delivered, only transported ¹ | The device is not intended to deliver energy to the patient. Energy is used to operate the device and communicate with the Smartphone Application. |
| Compatibility with environment and other devices | Probe is not known to conflict with other devices or cause environmental hazards | Same – the PeriCoach device has been tested in accordance with IEC60601-1-2 (2007) |
| Sterility | Probe does not need to be sterile. Appropriate cleaning procedure included in instructions for use. | Same |
| Body Materials | BP Empera Impact Polystyrene Type 514 | Medical grade silicone |
| Biocompatibility of body material | Biocompatible | Same - tested in accordance with ISO10993 standards |
| Electrical Safety | Unknown | Tested in accordance with IEC60601-1-2 (2007) and IEC60601-1(2005) |
| Chemical Safety | Body and electrodes constructed of chemically inert materials | Probe outer surface constructed of chemically inert materials and tested in accordance with ISO10993 standards. |
| Construction | Two mouldings enclosing two electrodes, ultrasonically welded together | Rigid polymer structure enclosed within a medical grade silicone outer layer |
| Shaft length | 76 mm | Same |

-

¹ Wording taken directly from 510(k) summary for Periform, K002617

| Parameters | Predicate: Periform (K002617) | PeriCoach (New device) |
|----------------------------------|----------------------------------|---|
| Width across electrodes/ sensors | 34 mm | 30-35 mm, across region containing sensor |
| Maximum flange dimension | 28.2 mm | 30-35 mm |
| Electrode surface area | 4.9cm2 x 2 | Sensor surface area is 11.8cm2 |
| Prescription only device | Yes | Same |

Conclusion: Both devices share common indications for use, usage environments and general principle of operation. The devices are both single patient reusable, nonsterile and are available by prescription only.

> The main differences between the devices are the way the pelvic floor muscle activity is determined, the materials used and the method of feedback to the user. Non-clinical testing demonstrates that the PeriCoach device raises no new safety or efficacy concerns and is therefore substantially equivalent to the legally marketed predicate device.